CEO Tim Moore will join 80+ other small cap and micro cap companies at leading investor event Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and cognitive […]
HAVN Life at Q1 2022 Virtual Investor Summit Read More »
The Company continues to grow its global retail footprint by partnering with the world’s largest ecommerce site Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, is pleased to
HAVN Life Natural Health Products Now Available on Amazon.com Read More »
The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, announces that the amalgamation agreement entered into with Spore Life Sciences Inc. (“Spore”), as announced on December 20, 2021, has
HAVN Life Announces Termination of Amalgamation Agreement to Acquire Spore Life Sciences Read More »
The Agreement allows HAVN Life to export naturally derived psilocybin from its Jamaica facility and grows roster of supply partners in the U.S. market Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as
HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market Read More »
Tim Moore and Michael Zavet to speak on Thursday, January 27 at 4:25pm EST Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of
HAVN Life Session at Psychedelic Capital: Jan 2022 by Microdose Read More »
Mr. Leong brings with him a wealth of scientific and regulatory experience Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind, is pleased to announce
HAVN Life Announces Gary Leong’s Appointment to Board of Directors Read More »
The Subscription-based Functional Mushroom Company has established a significant consumer base in the U.S. Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company developing natural health products and innovative therapies to support central nervous system health and enhance the capabilities of the mind,
HAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc. Read More »
The Company was able to export naturally derived psilocybin to their California-based Supply Partner, Mycrodose Therapeutics late last week. Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential active pharmaceutical ingredients (APIs)
CEO Tim Moore to present and host a Q & A for investors on December 8 at 2:30pm EST Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health
HAVN Life To Present at upcoming SNN Network Canada Virtual Event Read More »
